Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

A small, single-centre study has suggested that increasing sodium intake does not affect weight or kidney function in patients hospitalized for acute heart failure (HF) who are undergoing aggressive diuretic therapy.